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REGULATION OF INNATE IMMUNE CELL RESPONSE UNDER SUBACUTE/CHRONIC INFLAMMATORY CONDITIONS

by

SHUO “SEAN” NIU

Under the Direction of Yuan Liu, MD, PhD

ABSTRACT
Sub-acute/chronic inflammatory diseases are often associated with altered inflammatory
response, leading to increased host vulnerability to secondary inflammatory challenges.
In the first study, by employing streptozotocin (STZ)-induced diabetes in mice, we further
investigate mechanisms leading to enhanced polymorphonuclear leukocytes (PMN)
response under hyperglycemia. We show that existence of a proinflammatory state
associated with broad increases of macrophages in various organs plays a dominant role
in promoting PMN response in diabetic mice. Studies of PMN infiltration during
zymosan-induced peritonitis reveal that hyperglycemia enhances PMN recruitment
through increasing F4/80+ macrophages in the peritoneal cavity. Insulin reversal of
hyperglycemia reduces peritoneal macrophage numbers and ameliorates PMN

infiltration. Significantly increased macrophages are also observed in the liver, kidneys,
and intestines under hyperglycemia, and are attributable to exacerbated nephropathy and
colitis when respective inflammatory conditions are induced. We also find that significant
monocytosis of inflammatory F4/80+Gr-1+ monocytes from the spleen and macrophage
proliferation in situ synergistically contribute to the increased macrophage population
under hyperglycemia. In conclusion, our results demonstrate that STZ-induced
hyperglycemic/diabetic mice develop a systemic proinflammatory state mediated by
broad infiltration of macrophages. In the second study, we focus on the identification of
the carrier that binds to and delivers Shiga toxin 2(Stx2) to the target organ causing
hemolytic uremic syndrome (HUS). By employing a murine HUS model through coinjection of LPS-Stx2, we show that, adoptive transfer of CD11b+ leukocytes, but not
CD11b- leukocytes, RBC, platelets or plasma, isolated from mice with HUS induces HUS
in healthy recipients. Interestingly, we find that LPS priming of mice significantly
promotes CD11b+ leukocytes binding to Stx2. Compared to CD11b+ leukocytes from mice
without LPS priming, CD11b+ leukocytes isolated from mice after LPS priming
demonstrate higher frequencies of toxin binding and augmented potency to induce HUS.
In sum, our results demonstrate peripheral CD11b+ myeloid leukocytes act as effective
Stx2 carriers that deliver toxin to kidneys causing HUS and that LPS-induced
inflammation enhances the carrier capacity and aggravates HUS.

INDEX WORDS: Macrophage, PMN, Diabetes, Inflammation, Hemolytic uremic
syndrome, Shiga toxin 2
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1
1.1

INTRODUCTION

General introduction

Chronic diseases are often associated with altered inflammatory response, leading to
increased host vulnerability to new inflammatory challenges [1-3]. In the first study, by
employing streptozotocin (STZ)-induced diabetes as a disease model, we further
investigate mechanisms leading to enhanced neutrophil (polymorphonuclear leukocytes,
PMN) response under hyperglycemia and compare to that under chronic colitis. We show
that, different from colitis under which PMN response is significantly potentiated, the
existence of a proinflammatory state associated with broad increases in macrophages in
various organs plays a dominant role in promoting PMN inflammatory response in
diabetic mice. Studies of PMN infiltration during zymosan-induced peritonitis reveal that
hyperglycemia enhances PMN recruitment not through inducing a high level of IL-17,
which is the case in colitis, but through increasing F4/80+ macrophages in the peritoneal
cavity, resulting in elevations of IL-6, IL-1β, TNF-α, and CXCL1 production. Insulin
reversal of hyperglycemia, but not the neutralization of IL-17, reduces peritoneal
macrophage numbers and ameliorates PMN infiltration during peritonitis. Significantly
increased macrophages are also observed in the liver, kidneys, and intestines under
hyperglycemia, and are attributable to exacerbated nephropathy and colitis when
inflammatory conditions are induced by doxorubicin and dextran sulfate sodium (DSS),
respectively. Furthermore, analyses of monocyte production and macrophage
proliferation in tissues suggest significant monocytosis of inflammatory F4/80+Gr-1+
monocytes from the spleen and macrophage proliferation in situ synergistically
contribute to the increased macrophage population under hyperglycemia. In conclusion,
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our results demonstrate that STZ-induced hyperglycemic/diabetic mice develop a
systemic proinflammatory state mediated by broad infiltration of macrophages [4].

In the second study, we focus on another infectious/inflammatory disease, which is
hemolytic uremic syndrome (HUS) caused by the intestinal infection of Shiga toxin (Stx)–
producing Escherichia coli. HUS is a life-threatening complication characterized by
hemolytic anemia, acute kidney failure (uremia) and thrombocytopenia, and remains the
leading cause of acute renal failure in infants and young children [5, 6]. It remains
uncertain how Stx is transported or delivered from the intestine (original infectious site)
to the kidney (distant end organ), where it directly damages glomerular epithelial cells [79], since studies have excluded the possibility that Stx spreads by passive dissemination,
as no free Stx have been detected in the serum of HUS patients. Instead, circulating blood
cells (e.g., leukocytes) have been suggested to serve as the carrier that delivers Stx to
distant organs, but the identification of the specific cell type remains controversial [10,
11]. In this study, by employing a murine HUS model through intraperitoneal co-injection
of LPS plus Stx2, we further investigate the carrier that delivers Stx2 to the target distant
organs in vivo. We show that, adoptive transfer of white blood cells (WBC), but not red
blood cells (RBC), platelets (PLT) or plasma, isolated from mice with HUS is able to
induce HUS in previously healthy recipients. Ex vivo incubation with Stx2 of isolated
WBC, RBC or PLT from LPS-primed mice followed by adoptive transfer into recipients
also confirms that only receiving Stx2 pre-treated WBC, not RBC or PLT, leads to HUS.
Further separation of WBC into CD11b+ leukocytes (myeloid lineage cells) and CD11bleukocytes (non-myeloid cells) demonstrates that only CD11b+ leukocytes are capable of
inducing HUS through Stx2 binding and delivering. Interestingly, we found that CD11b+
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leukocytes from LPS-primed mice readily induced HUS after exposure to Stx2, whereas
the same treated CD11b+ leukocytes from healthy mice without LPS priming exhibited
weaker effects. In conclusion, our results demonstrate that during the development of
HUS in mice, Stx2 is carried and delivered to the target organs by peripheral CD11b+
leukocytes in vivo. Although more investigations are required, these results highly
suggest that LPS-induced systemic inflammation plays a significant role in “priming”
CD11b+ leukocytes for binding to Stx2; this effect of LPS renders these leukocytes to
become effectual toxin carriers resulting in toxin dissemination to distal organs and
aggravation of HUS.

1.2 Background
1.2.1 Macrophage-PMN mediated acute inflammation
Macrophage-PMN mediated inflammation is a central component of many diseases.
Active inflammation features many pathophysiological conditions including infections by
various pathogens, and non-infectious tissue/organ disorders such as inflammatory
bowel disease (IBD), cardiovascular disease, diabetes, arthritis, and even cancer.
Activation of macrophage-PMN, and their inflammatory responses are the most
characteristic events during active inflammation and directly impact the consequence of
the diseases. In general, immune surveillance macrophages first sense the pathogen
infection or tissue stress, followed by producing a broad spectrum of chemical proinflammatory mediators. These mediators (such as cytokines and chemokines) stimulate
the nearby microvasculature and induce large amount of polymorphonuclear leukocytes
(PMN) to rapidly transmigrate across the blood vessel wall, and infiltrate into the
inflammatory site. After arrival at the site, PMN release potent agents such as reactive
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oxygen species (ROS), reactive peptides and proteases, as well as perform phagocytosis,
thereby eliminating pathogens, irritants and damages cells [12-15]. In addition, more
monocytes are also recruited by the mediators and infiltrate into the inflammatory area.
These freshly recruited macrophages are pro-inflammatory (classically activated
macrophages or M1 macrophages), which have enhanced antimicrobial functions
secreting pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and
interleukin-1beta (IL-1β).

These macrophages also produce nitric oxide (NO) and

superoxide which brings significant damage to the invading pathogens and irritants.
Different from cytotoxic CD8+ T cells or natural killer cells, which eliminate aberrant
particles or cells individually, PMN-mediated destruction is localized and robust. Thus,
under well-controlled conditions, macrophage-PMN-centered inflammation represents
the most powerful innate immune mechanism to eliminate pathogens and irritants, as
well as initiates the process of tissue repairing.

However, vigorous macrophage-PMN functions under dysregulated conditions are the
underlying causes for exacerbated tissue damage, and often extensively aggravates the
existing pathological disorders. For instance, in atherosclerosis, macrophage
accumulation in the atherosclerotic plaques is the major contribution to the non-resolving
inflammatory response and the progression of this disease [16, 17]. Moreover, during
acute myocardial attack or cerebral-vascular accident, PMN infiltrating myocardium or
the brain features prominently at the post-ischemic reperfusion stage and is considered
to be the major reason leading to further and permanent tissue damage[18-20]. Similarly,
exaggerated PMN infiltration is the direct cause of tissue/organ damage and loos of
functions associated with other diseases such as IBD [21-23], and arthritis [24, 25].
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Therefore, like a double-edged sword, macrophage-PMN inflammatory response is both
important and extremely dangerous. Appropriate control of these innate immune cells
remains as an important mission for improving therapeutics for many diseases.

1.2.2 Diabetes and innate immune cells
Diabetes mellitus (diabetes) is a disease that has become a massively growing medical
problem that affects more than 300 million people throughout the world (7% of the
world’s adult population). Patients with diabetes have an increased susceptibility to
develop many complications such as infection, skin lesion, cardiovascular disease, and
diabetic nephropathy leading to end stage renal failure [26-30]. Persistent or poorly
controlled hyperglycemia contributes to an elevation in both morbidity and mortality in
diabetic patients. It is a worldwide disease spreading not only in developed countries, but
also in developing ones. In USA, the total estimated cost of diagnosed diabetes in 2012 is
$245 billion, including $176 billion in direct medical costs and $69 billion in reduced
productivity. Therefore, diabetes and its complications are critical medical concerns that
are threatening the economy and public health of the entire world.

Diabetes is a disorder of the metabolism identified by hyperglycemia (high blood glucose
level) resulting from insufficient insulin producing (type 1 diabetes), or insulin resistance
(type 2 diabetes). Both type 1 and type 2 diabetes have been characterized not only as
metabolic but also immune disorders. Macrophage-PMN-mediated inflammatory
response is a central component that contributes to the progression of diabetes and its
complications, such as skin lesion, atherosclerosis and chronic kidney disease [28-30],
and is believed to provide a significant connection that links immune dysfunction and
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metabolic disorder [31]. The studies of mechanisms that regulate innate immune cells in
diabetes are intricate, and even controversial in many aspects. Previous studies showed
that adhesion, chemotaxis and phagocytosis of macrophage and PMN in diabetes were
both impaired [32, 33], while other studies show adhesion, migration and TNF-α
production of macrophages are enhanced by hyperglycemia [34]. In contract to healthy
controls stimulated with LPS, monocytes from patients with type 1 diabetes produced
higher amount of pro-inflammatory cytokine IL-6 [32]. Hyperglycemia also elevated
monocyte-chemoattractant-protein-1 (MCP-1) production from diabetic endothelial cells,
thus attracting more macrophages that potentially promoted arteriosclerosis [35].
Moreover, obesity in type 2 diabetes triggered monocytes infiltrating into the adipose
tissue, where these infiltrated monocytes/macrophages further promoted insulin
resistance via producing pro-inflammatory cytokines [36, 37]. Collectively, the effects of
hyperglycemia on macrophage-PMN function and response are still largely unknown and
required further addressed.

As the word origin of Diabetes Mellitus meaning “to pass through (excessive discharge of
urine) honeyed or sweet”, hyperglycemia is the very character shared by all types of
diabetes that results in a global micro-environmental change to the whole-body systems
including immune system. Persistent or poorly controlled hyperglycemia contributes to
an elevation in both morbidity and mortality in diabetic patients. Therefore,
understanding the direct regulation of hyperglycemia to macrophages-PMN response is
extremely urgent and clinically significant.
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1.2.3 Shiga toxin and hemolytic uremic syndrome
1.2.3.1 Disease background
Shiga toxin (Stx)-producing E. coli (STEC) represents a serious life-threatening food
borne pathogen and is a major health problem still in the United States and world-wide.
It is estimated that STEC causes over 265,000 illnesses each year in the US with more
than 3,600 hospitalizations and 30 deaths [5]. Infections caused by STEC lead to
bacterial-induced intestinal inflammation characterized by heavy diarrhea (watery and
bloody) and colitis. However, the subsequent development of hemolytic uremic syndrome
(HUS), which is characterized by microangiopathic hemolytic anemia, thrombocytopenia,
and acute renal failure, is the main reason for the high rates of mortality associated with
such disease [7, 38, 39]. In fact, HUS is the leading cause of renal failure in infants and
young children [40, 41]. The inability to predict which patients will recover spontaneously
and which will develop HUS remains a significant dilemma for clinicians [42]. HUS
develops at the post-acute stage of infection and is associated with the spread of Shiga
toxin (Stx) from the intestines to other distal organs, such as the kidney. Currently there
are no specific therapeutics available for treatment of STEC-associated HUS, and therapy
is primarily supportive. A major obstacle in combating HUS is that traditional antibiotic
therapy is contraindicative because it shows promotion of toxin expression from the
lysogenized phage that typically carries Shiga toxin (Stx) genes, thus, exacerbating the
infection [43]. Therefore, novel therapeutic strategies are urgently needed for controlling
this serious infectious disease.

E. coli O157:H7, the strain most frequently associated with the development of HUS, was
first described in 1982 in four patients with bloody diarrhea [44]. The initial outbreak was
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associated with two outlets of the same fast-food chain, and illness was linked to
undercooked hamburgers. Many outbreaks have occurred since then with one of the most
severe occurring from May 2011- July 2011 in several European countries, particularly
northern Germany (Hamburg), which experienced one of the largest death tolls related to
HUS ever reported [45]. More recently, other sources for E. coli 0157:H7 have been
identified, including apple juice and cider; raw vegetables such as lettuce and spinach;
raw milk; and processed foods such as salami [46].

1.2.3.2 Shiga toxin
STEC produces two types of bipartite toxins, Stx1 and Stx2, which belong to a large family
of prokaryotic A:B toxins that include, pertussis, diphtheria, cholera, and ricin [47] and
consists of one large enzymatically active A subunit (~32 kDa) and 5 smaller B subunits
(~8 kDa each). The holotoxin binds via the B- subunit pentamer to the lipid raftassociated glycolipid receptor globotriacylceramide (Gb3), located on the surface of target
cells, in particular the kidney glomerular endothelium, where the expression of the Stx
receptor is most abundant [48]. After toxin uptake by way of endocytosis, Stx undergoes
retrograde trafficking through the Golgi apparatus and endoplasmic reticulum to the
cytosol, where it specifically cleaves an adenine from the 28S rRNA, inactivating the
ribosome and inhibiting protein synthesis [49]. Additionally, it has been found that Stx
also depurinates DNA, resulting in host cell apoptosis [8].
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1.2.3.3 Potential carriers of Stx
For non-invasive STEC to cause HUS, Stx must be delivered or transported from the
intestine to the kidney. It remains a dilemma how Stx travels from STEC-infected
intestines to kidneys, though studies have excluded the possibility that Stx spreads by
passive dissemination, as no free Stx have been detected in the serum of HUS patients.
Instead, circulating leukocytes have been suggested to serve as the carrier that delivers
Stx to distant organs [10, 11]. In human, PMN have been implicated to be the carrier.
Direct binding of Stx to human PMN was observed and this binding was interfered by
LPS, suggesting Toll-like receptor 4 (TLR4) to be the receptor [10, 50-52]. However, other
studies either failed to replicate Stx-neutrophil binding or demonstrated that the binding
was rather weak and unspecific, raising uncertainty of whether PMN are the toxin carrier
[53, 54]. Stx binding to leukocytes was also shown using isolated porcine peripheral blood
leukocytes in vitro; however, whether these leukocytes were responsible for toxin delivery
in vivo leading to HUS was not studied [55]. In mice, a study demonstrated that Stx2 was
capable of binding to neutrophils, but this binding is through Gb3 and leads to the toxin
internalization. Therefore, this study not only contradicted to the finding in humans in
which Stx-neutrophils binding is independent of Gb3 [56], but also raised a question of
whether neutrophils would deliver toxin without degrading it intracellularly. In addition
to these dilemmas, a recent study found Stx in serum microvesicles, further baffling the
exact carrier for Stx elusive. Moreover, most of the above experiments identifying the
toxin carrier were in vitro cell binding assays, and there is a need for approaches that
determine the relevance of Stx delivery causing the actual disease of HUS in vivo.
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1.3 Murine disease models
1.3.1 STZ-induced hyperglycemia/type 1 diabetes
STZ, originally identified as an antibiotic in the late 1950s [57], has been widely used to
induce diabetes/hyperglycemia in experimental animals [58]. STZ is a glucose analog
(glucosamine-nitrosourea compound), which enters the pancreatic β cells through
glucose transporter 2 that is highly expressed on the surface of β cells [59, 60]. STZ is
highly toxic to β cells by causing DNA alkylation, which induces the activation of poly
ADP-ribosylation, a process that contributes to the diabetogenicity of STZ more than DNA
damage itself [61]. As shown in Figure 1, poly ADP-ribosylation results in the depletion of
NAD+ and ATP, and the augmented ATP dephosphorylation increases the supply of
substrate for xanthine oxidase, which elevates the production of superoxide radicals.
Moreover, STZ also increases the amount of nitric oxide to a toxic level. Consequently,
pancreatic β cells undergo necrosis due to the action of STZ, and production of insulin is
ceased, therefore resulting in permanent hyperglycemia/type 1 diabetes, which can be
temporarily reversed after the administration of insulin.

To induce permanent hyperglycemia/diabetes, STZ is administrated intravenously,
intraperitoneally, or subcutaneously into the experimental animal, usually in multiple low
doses (30-50 mg/kg). During the first several days, animal may develop hypoglycemia
due to a transient insulitis that is also caused by STZ [58]. After 10-14 days, hyperglycemia
will be developed, and remain for the rest of life. There are several advantages of utilizing
this STZ-induced diabetic mouse model compared to other models (e.g., high-fat-dietinduced type 2 diabetes). First, hyperglycemia is the only major inflammatory
pathogenesis in this STZ model, where no other systemic inflammatory factors, such as
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obesity, are involved, therefore providing a more isolated/independent system for the
purpose of studying the regulation of immune system under hyperglycemic condition.
Second, STZ induces type 1 diabetes, which is insulin dependent that can be
treated/reversed by the administration of insulin, thus affording a high degree of
controllability and reproducibility.

Figure 1.1 The mechanism of STZ-induced toxic events in β cells of rat pancreas.
MIT-mitochondria; XOD-xanthine oxidase[61]
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1.3.2 DSS-induced colitis
Heparin-like polysaccharide DSS is the most common chemical used to induce
experimental colitis in mice [62, 63]. By routinely administration of DSS within daily
drinking water, a form of mouse colitis is developed that mimics the clinical and
histological features of human ulcerative colitis (a form of IBD in human), as a dose
dependent manner [64]. Characteristics of DSS-induced colitis include weight loss,
diarrhea, bloody stool, reduced colon length, loss of colon epithelial tissue, and crypt
architecture disruption. Proinflammatory cytokines and chemokines, such as IL-1β, IL-6,
IL-8, and TNF-α, are markedly elevated, which results in the recruitment of circulating
inflammatory monocytes/macrophages, and most predominantly PMN into the distal
colon. Furthermore, marked elevation of IL-17 at the post-acute/chronic stage [1, 21, 65,
66] of DSS-induced colitis has been observed. According to our studies and studies by
others [67-70], under the colitic condition, IL-17 is tightly associated with enhanced PMN
response through at least two mechanisms: i) promoting granulopoiesis, thus increasing
the PMN supply, and ii) potentiating PMN response leading to enhanced PMN
chemotaxis, ROS production, etc.

After the administration of DSS, the epithelial monolayer lining the distal colon is
damaged, which allows the dissemination of proinflammatory intestinal contents (e.g.,
bacteria and their products) into the lamina propria. However, the mechanism of how
DSS causes disruption in the distal colon remains unknown. Some studies suggest that
dextran sulfate inhibits ribonuclease action [71, 72], but the mechanism of how DSS
penetrates the cell is also unclear. Recent studies indicate that DSS combines with
medium-chain-length fatty acids that are present in the colonic lumen to form nano-
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lipocomplexes, which are able to fuse with colonocyte membranes and further activate
downstream inflammatory signaling pathways inside the cytoplasm [73]. Nevertheless,
DSS-induced colitis is a well-recognized, simple, and consistent model for assessing both
acute and chronic colitis.

1.3.3 LPS-Stx2-induced hemolytic uremic syndrome
This murine HUS model was first established by Keepers et al. [74] by the intraperitoneal
administration of Stx2 combined with LPS. Neither Stx2 nor LPS alone is able to mimic
HUS in the mouse, but combining Stx2 with LPS recapitulates the human HUS in both
clinical signs and symptoms, including the clinical diagnostic hallmark triad of hemolytic
anemia, thrombocytopenia, and renal failure [5]. In particular, increased reticulocytes
and Howell-Jolly bodies that are observed in this murine model demonstrate hemolytic
anemia. A very low platelet count represents thrombocytopenia. Elevated serum
creatinine and blood urea nitrogen (BUN) levels are the evidence of renal
dysfunction/renal failure. The mice also exhibit neutrophilia and monocytosis that are
described in clinic studies [38, 41]. Pathological changes in the glomeruli of kidney tissue
are consistent with the features of clinical HUS.

In our study for the identification of the potential carrier of Stx2 in mice with HUS, to
establish a steady HUS model, we utilized the LPS plus Stx2 administration strategy. In
particular, mice were first intraperitoneally injected with LPS, 24 hours prior to the Stx2
intraperitoneal administrations for three times in a 24-hour-interval. As early as 24 hours
after the first dose of Stx2 injection, the complete HUS triad of hemolytic anemia,
thrombocytopenia, and renal dysfunction begun to develop in the mice. In summary, co-
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injection of LPS and Stx2 intraperitoneally is sufficient to recapitulate human HUS in
experimental mice, which provides a reproducible model for the study of HUS.
Furthermore, it does not require live bacteria, since HUS is a toxemia but not a bacteremia
[42].
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2 BROAD MACROPHAGE INFILTRATION LEADS TO A
PROINFLAMMATORY STATE IN STREPTOZOCIN-INDUCED
HYPERGLYCEMIC MICE

Shuo Niu1, Zhen Bian1, Alexandra Tremblay1, Youqun Luo1, Kobby Kidder1, Ahmed
Mansour1, Ke Zen2 and Yuan Liu1

1

Program of Immunology & Molecular Cellular Biology, Department of Biology, Center

for Diagnostics & Therapeutics, Center of Inflammation, Immunity & Infection, Georgia
State University, Atlanta, GA 30302, USA.
2 State

Key Laboratory of Pharmaceutical Biotechnology, Nanjing Advanced Institute for

Life Sciences, Nanjing University, Nanjing, Jiangsu, 210093, China

2.1 Introduction
An active inflammatory response often starts in local tissues where afflicted cells and
immunological surveillance cells (viz. tissue macrophages) respond to infection and/or
injury, and produce potent proinflammatory mediators [12-15]. These mediators (i.e.
cytokines, chemokines, lipids, and complements) stimulate the nearby microvasculature
and attract peripheral PMN to transmigrate across endothelial linings and infiltrate
inflammatory tissues. These inflammatory PMN then perform potent anti-pathogen and
tissue-damaging functions to eliminate infectious aliens and remove injured cells [75-78].
Effectively mounting such a leukocyte-centered inflammatory response is imperative for
innate immunity; failure of this response directly indicates immune deficiency [79-84].
However, exaggerated leukocyte inflammatory response is detrimental, often leading to
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aggravated tissue damage and prolonged disease conditions [17, 23-25, 85, 86].
Therefore, like that of a double-edged sword, active inflammation is extremely important,
but also highly dangerous.

The specific mechanisms that control this inflammatory response under various disease
conditions vary and remain an enigma. In our previous studies of zymosan-induced
peritonitis in mice, we had observed that PMN infiltration into the peritoneum is
significantly enhanced in mice that had been preconditioned with colitis, type-1 diabetes,
or other chronic inflammatory conditions [1, 2]. Furthermore, the enhanced PMN
response under colitis was found to be associated with marked elevation of IL-17 at the
post-acute/chronic stage [1, 21, 65]. According to our studies and also studies by others
[67-70], IL-17 promotes PMN inflammatory response through at least two mechanisms:
i) promoting granulopoiesis, thus increasing the PMN supply, and ii) potentiating PMN
response leading to enhanced PMN chemotaxis, ROS production, etc. However, it is
unclear whether IL-17 plays an essential role as well in enhancing PMN response under
other conditions.

In this study, we further examined mechanisms that enhance PMN response under
diabetes using an STZ-induced type-1 diabetes model. We found that IL-17 plays a
negligible role in this condition; instead, diabetes-associated hyperglycemia induces a
significant expansion of the macrophage population in multiple organ tissues. This
increased population disposes a systemic hypersensitive state that, upon inflammatory
challenge, triggers a hyper-inflammatory reaction and increases proinflammatory
cytokines and chemokines through which promote PMN infiltration.
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2.2 Materials & Methods
2.2.1 Mice & Disease models
C57BL/6 mice (6-10 weeks old, 18-22g) and B6.Cg-Lepob mice (ob/ob mice, 10-12 weeks
old, 35-40g) were purchased from The Jackson Laboratory and were housed in a
pathogen-free animal facility. STZ-induced type 1 diabetes [87-89] was established by
subcutaneous (s.c.) administration with STZ (Sigma-Aldrich, freshly prepared in citrate
buffer, pH 4.5), at the dose of 50 mg/kg of body weight or a lower dose, 25 mg/kg of body
weight (volume: 0.2 ml per mouse), for five consecutive days. Diabetes/hyperglycemia
was confirmed by testing the blood glucose level using the OneTouch® glucose monitoring
system (LifeScan). To treat diabetic mice with insulin, STZ-injected mice with confirmed
hyperglycemia (blood glucose level > 200mg/dl) were administered with insulin (1UI/kg,
0.2 ml, s.c.) twice a day.

To induce colitis, 2% DSS (MP Biomedicals) dissolved in pure water was given to mice as
the drinking water [1]. The colitis disease activity index (DAI) was determined by
combining scores of 1) body weight loss (0, none; 1, 1-5%; 2, 5-10%; 3, 10-15%; 4, >15%),
2) stool consistency (0, normal; 2, loose stool; 4, diarrhea), and 3) stool blood (0, negative;
2, positive; 4, gross bleeding) [90].

To induce peritonitis, 0.5 mg zymosan (zymosan A, Sigma-Aldrich) in 0.5 ml PBS was
given intraperitoneally (i. p.) [91]. At different time points (0, 2, 4, 6, 8 and 16 h) following
the zymosan administration, mice were euthanized and cells inside the peritoneum were
lavaged into 5ml PBS. Total peritoneal cell numbers were counted under the microscope.
PMN that infiltrated the peritoneum were labeled with fluorophore-conjugated anti-
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mouse Ly6G antibodies (BioLegend, 1:1000, room temperature, 2 h), and analyzed by
flow cytometry.

Doxorubicin-induced nephropathy was established by intravenous (i.v.) administration
of doxorubicin hydrochloride (Sigma-Aldrich) at doses of 20 mg/kg or 30 mg/kg (in 0.3
ml PBS, i.v. once) [92, 93]. Urine samples were collected daily via gentle bladder massage
and proteinuria was tested using an Albumin Mouse ELISA kit (Abcam) according to the
manufacturer’s protocol. At day 7 of doxorubicin (30 mg/kg, once) administration, mice
were euthanized, kidneys were harvested and excised for immunohistochemistry (IHC)
staining described blow.

2.2.2 Tissue sectioning and staining
Kidney, liver, and colon tissues excised from mice were embedded in Richard-Allan
Scientific™ Neg-50™ frozen section medium (Thermo Scientific) followed by sectioning
at a thickness of 10µm using a Cryostat microtome. For immunohistochemistry (IHC)
staining, the tissue slides were treated with 0.1% H2O2, followed by blocking with 10%
normal goat serum (NGS). Macrophage staining was performed using a rat anti-mouse
F4/80 antibody (BioLegend, 1:500) at 4oC for 16 h, and an HRP-conjugated goat anti-rat
secondary antibody (1:2000, room temperature, 30 mins), followed by color development
using 3, 3'-diaminobenzidine (DAB) (BD Biosciences). Tissue counterstaining was
performed using hematoxylin (8 mins). For immunofluorescence (IF) staining, NGSblocked tissue sections were incubated with Alexa Fluor 488-conjugated anti-mouse
F4/80 antibody (BioLegend, 1:500, room temperature, 2 h) or a non-conjugated antiF4/80 antibody (1:500, room temperature, 2 h) followed by detection using Alexa Fluor
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594-conjugated goat anti-rat IgG (Invitrogen, 1: 2000, room temperature, 30 mins). To
test macrophage proliferation in situ, tissue sections were permeabilized with 0.05%
Triton X-100 in PBS, and stained with a FITC-conjugated anti-mouse Ki-67 antibody
(BioLegend, 1:500, room temperature, 2 h).

2.2.3 Leukocyte adoptive transfer
Total bone marrow cells were obtained by flushing femur cavities of healthy mice and
diabetic mice. After lysis of RBC using RBC lysis buffer (0.15 M NH4Cl, 10 mM NaHCO3,
0.1 mM EDTA), cells were applied to Percoll™ (GE Healthcare) density gradients to
separate mature PMN (1800xg, 18°C, 40 mins), which were settled at the interface
between Percoll densities of 60% and 70% [94]. The obtained PMN samples of healthy
mice and diabetic mice were then separately labeled with orange and green fluorescence
dyes, 5,6-((4-chloromethyl) benzoyl) amino) tetramethylrhodamine (CMTMR, Life
Technologies) and carboxyfluorescein succinimidyl ester (CFSE, Life Technologies),
respectively. For adoptive transfer, CMTMR and CFSE-labeled PMN (1.5 x 106 cells each
color) were mixed and intravenously (i.v.) injected into a recipient mouse through a tail
vein. To test PMN response in vivo, zymosan-peritonitis was induced in recipient mice as
described earlier and fluorescence-labeled PMN infiltration into the peritoneal cavity at
2 h post-zymosan injection was analyzed microscopically after the peritoneal lavage.

2.2.4 Reactive oxygen species (ROS) assay
A luminal-based assay was used to test PMN production of ROS upon phorbol myristate
acetate (PMA) (Sigma-Aldrich) stimulation. Briefly, isolated PMN (1 x 106) from bone
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marrow as described earlier were incubated in HBSS (with calcium and magnesium)
containing 1mM luminol (Sigma-Aldrich) at 37°C. After stabilization, PMN were
stimulated with PMA (1µM) and photons released from the reaction were immediately
recorded at a 30-second interval for 30 minutes using a microplate luminometer (LMax
II 384, Molecular Devices), followed by analyses using a SoftMax Pro software (Molecular
Devices).

2.2.5 Measurement of cytokines
Whole blood from mice was collected without anti-coagulation and the serum was
isolated through centrifugation (2000xg, 4°C, 5 mins). Cytokines including IL-1β, IL-4,
IL-6, IL-10, IL-17A, IFN-γ, TNF-α, MCP-1, G-CSF and GM-CSF in the serum were assayed
by standard sandwich ELISA in 96-well plates using capture and detecting antibodies
obtained from BD Biosciences or BioLegend. Purified recombinant murine cytokines
purchased from PeproTech were used as positive controls and concentration references.
To detect cytokines released by in vitro-treated macrophages, F4/80+ peritoneal
macrophages obtained from mouse peritoneal lavage were cultured in the 24 well-culture
dish for 16 h and treated with zymosan (0.1 mg/ml, 37oC). At different time points after
the administration of zymosan, the cell-free supernatants were collected, followed by
ELISA detection of cytokines.
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2.2.6 Flow cytometry assays of leukocytes from peripheral blood, spleen
and bone marrow
Mouse peripheral blood were collected by cardiac puncture with anti-coagulation (0.1
mM EDTA). After lysis of RBC using RBC lysis buffer (0.15 M NH4Cl, 10 mM NaHCO3,
0.1 mM EDTA), white blood cells were collected followed by labeling with fluorophoreconjugated antibodies against murine Gr-1 and F4/80 (both from BioLegend, 1:1000,
room temperature, 30 mins) and analyses by flow cytometry (LSR Fortessa, BD
Biosciences). Mouse splenocytes were isolated from the whole spleen, and bone marrow
leukocytes were harvested from mouse femur and tibia bones. After lysis of RBC, these
cells were labeled with fluorophore-conjugated anti-mouse Ly6C and Ly6G antibodies
(both from BioLegend, 1:1000, room temperature, 30 mins) followed by flow cytometry
analyses. In particular, monocytes populations were represented by F4/80+ cell groups in
the peripheral blood, or Ly6Chigh cell groups in the spleen and the bone marrow. PMN
populations were represented by Gr-1++ F4/80- cell groups in the peripheral blood, or
Ly6Ghigh cell groups in the spleen and the bone marrow.

2.2.7 Statistical analyses
Data represent at least three independent experiments and are expressed as the mean ±
SD. Normal distributed variables were compared using Student’s t-test. The reported p
value was 2-tailed. Differences were considered statistically significant at P < 0.05, as
analyzed using the Student t-test for paired samples and one-way ANOVA for k > 2
samples.
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2.3 Results
2.3.1 Distinctive mechanisms regulate PMN response under STZ-induced
diabetes and DSS-induced colitis
Previously, we had observed that mice under different inflammatory conditions,
including STZ-induced diabetes and DSS-induced colitis, experience enhanced PMN
inflammatory response [1]. In particular, we found that this PMN phenotypic change
under colitis is associated with IL-17 induction. In this study, we further investigated
mechanisms that cause the PMN response change under STZ-induced diabetes. As shown
in Figure 2.1 A, mice administered with STZ rapidly developed hyperglycemia in a few
days, where a higher dose (50 mg/kg, 5 x) led to a blood glucose level of 350-550 mg/dl
and a lower dose (25 mg/kg, 5 x) led to a blood glucose level varying between 200-400
mg/dl. Furthermore, the hyperglycemic condition was maintained for an extended period
of time unless given insulin, which mitigated hyperglycemia in STZ-treated mice. We
further separated mice into two groups: one group had the blood glucose between 200350 mg/dl, and the other group had a relatively higher level, >350 mg/dl. To study how
hyperglycemia affects PMN response, two groups of diabetic mice with different levels of
blood glucose, or with insulin treatment, were i.p. challenged with zymosan to induce
acute peritonitis. As shown in Figure 2.1 B, zymosan challenge induced rapid PMN
infiltration into the peritoneum for all mice. However, when comparing mice without STZ
administration (ctl.) and those with STZ-induced hyperglycemia, the latter displayed a
significant increase in the number of PMN as well as an earlier onset during which PMN
infiltrate. Specifically, more than 5 x 106 PMN were accumulated in the peritoneum of
mice with hyperglycemia at 2 h post the zymosan challenge, whereas only minimal PMN
infiltration was detected in non-diabetic control mice. When PMN infiltration had
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climaxed (4-6h), hyperglycemic mice had displayed a greater number of PMN infiltrating
the peritoneum than that of the control. There were only slight differences in PMN
response in hyperglycemic mice with blood glucose level of 200-350 mg/dl versus those
of > 350 mg/dl. Through insulin treatment, the alleviation of the hyperglycemic condition
completely eliminated the enhanced PMN inflammatory response, both the onset and the
increased number, during zymosan-induced peritonitis.

Indeed, the manner of enhanced PMN infiltration at 2 h post-zymosan challenge in mice
with hyperglycemia was highly similar to that in mice with chronic colitis (Figure 2.1 C).
Colitis in mice was induced by 2% DSS via drinking water (Figure 2.1 D), and, consistent
with our previous studies, IL-17 was significantly induced when colitis lasted over 8-9
days [1, 2]. Experimental colitis is associated with prominent induction of IL-17 had also
been reported by others [66]. Testing zymosan-induced peritonitis in mice with a high
level of IL-17 on day 10 of DSS-induced colitis observed markedly enhanced PMN
infiltration into the peritoneum (Figure 2.1 C). Consistent with previous reports [1, 2, 66],
this colitis-associated enhancement of PMN response was associated with the effect of IL17, as it could be eliminated by IL-17 neutralization (Figure 2.1 C). In contrast,
neutralization of IL-17 in mice with hyperglycemia, either 200-350 mg/dl or >350 mg/dl,
failed to reduce PMN infiltration (Figure 2.1 C). Analyses of cytokines in serum confirmed
different cytokine profiles in mice with colitis versus those with hyperglycemia. In
particular, IL-17 was highly elevated only in mice under colitis, but not hyperglycemia
(Figure 2.1 E). In fact, no particularly high levels of cytokines, except moderate increases
in IL-6 and MCP-1 (Figure 2.1 E), were detected in mice with hyperglycemia for even 5
months. Thus, although colitis and hyperglycemia both displayed enhancement of PMN
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inflammatory response, the key mechanism involved in these two conditions are
different. IL-17, which is essential in colitis, plays a trivial role in regulating PMN response
under hyperglycemia.

Since a previous study has shown that PMN function was primed under colitis [1], we
tested if this would also be the case in mice with hyperglycemia. For these experiments,
PMN samples isolated from different mice were tested for ROS production upon PMA
stimulation. As shown in Figure 2.1 F, compared to PMN from control mice, PMN from
mice with colitis and hyperglycemia both displayed increased ROS production; however,
the former PMN consistently displayed even higher levels than the latter. These results
suggest that PMN under hyperglycemia and colitis were both functionally primed;
however, the condition of colitis provided a mechanism that is more potent in priming
PMN than that of hyperglycemia. Again, IL-17 played an essential role in colitis but not
hyperglycemia; neutralization of IL-17 reversed the enhanced ROS production in PMN
isolated from colitic, but not diabetic, mice (Figure 2.1 G).

2.3.2 Hyperglycemia increases peritoneal macrophage population and
escalates zymosan-induced peritonitis
Despite that PMN displayed less priming under hyperglycemia compared to colitis, the
enhanced PMN recruitment during peritonitis in mice under either condition was similar
(see Figure 2.1 B). These results suggest that another mechanism(s), in addition to PMN
priming, synergistically promotes PMN response under hyperglycemia. To identify this
mechanism(s), we further analyzed zymosan-induced peritonitis and found that
inflammatory cytokines produced in mice with hyperglycemia were much higher than
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mice with colitis. As shown in Figure 2.2 A, significantly higher levels of IL-6 and CXCL1
(also termed KC or IL-8) were detected in the peritoneal cavity and in the serum during
peritonitis in hyperglycemic mice than those in colitic mice, and both being higher than
those in the control. This suggests that macrophage inflammatory responses in peritonea
of hyperglycemic and colitic mice were upregulated. We lavaged peritoneal F4/80+
macrophages, the principle cells producing IL-6 and CXCL1 [95, 96], and examined their
function ex vivo. Interestingly, lavaging the peritoneum of hyperglycemic mice recovered
more than double the amount of F4/80+ macrophages than those recovered in colitic and
control mice. As shown in Figure 2.2 B, more than 17 x 105 macrophages were recovered
from hyperglycemic mice with blood glucose levels below or above 350 mg/dl, versus 8.4
± 1.5 x 105 and 8.1 ± 0.5 x 105 from colitic and control mice, respectively. Furthermore,
treatment of diabetes with insulin reduced the number of macrophages in the
peritoneum. Testing cytokine production from peritoneal macrophages by zymosan
challenge ex vivo revealed markedly higher levels of total IL-6, CXCL1, IL-1β, and TNF-α
produced by macrophages from hyperglycemic peritoneum than those from colitic,
control, or insulin-treated mice (Figure 2.2 C, Total). However, these increases were
contingent upon higher macrophage numbers; calculation of cytokine production by
isolated macrophages revealed that individual macrophages from hyperglycemic mice did
not produce more cytokines than control macrophages from healthy mice, and actually
lower levels than macrophages from colitic mice (Figure 2.2 C, Individual). Therefore,
these results suggest that increases in the macrophage number, but not the macrophage
functionality, served as a dominant reason for promoting the macrophage-mediated
inflammatory response during zymosan-induced peritonitis in hyperglycemic mice. In
contrast, macrophages from colitic mice displayed increases in cytokine production
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individually, suggesting these macrophages were functionally primed. In addition, we
observed that macrophages from insulin-treated mice produced much less TNF-α than
those from healthy mice (Figure 2.2 C), and this has also been reported previously [97,
98].
Thus, the increased macrophages in the peritoneum under hyperglycemia likely played a
critical role, in addition to moderate PMN priming, in promoting an inflammatory
response during peritonitis. To further test the role of peritoneal microenvironment, we
performed PMN adoptive transfer experiments. For these experiments, PMN isolated
from healthy and hyperglycemic mice were labeled with CMTMR (red) and CFSE (green),
respectively, and then were mixed at 1:1 ratio followed by transfer into healthy or diabetic
mice. Zymosan-induced peritonitis was subsequently induced in the recipient mice. In
healthy recipient mice, CFSE-labeled PMN that originated from hyperglycemic mice
displayed slightly more (~20%) infiltration than CMTMR-labeled PMN that were from
healthy mice (Figure 2.2 D-E). This confirmed that PMN from the donor hyperglycemic
mice were moderately primed. However, in recipient mice that were hyperglycemic, not
only CFSE-labeled PMN from diabetic mice, but also CMTMR-labeled PMN from healthy
mice, displayed enhanced infiltration, though the former was greater. At 2 h postzymosan administration, double the number of PMN (green or red) infiltrated the
peritoneum in hyperglycemic recipients than that in healthy recipients. As expected,
insulin treatment of recipient mice completely eliminated the promoting effect on PMN
infiltration by diabetes. Together, these results confirmed that the hyperglycemic
peritoneum, which had increased numbers of macrophages and produced elevated
proinflammatory cytokines, significantly promoted PMN infiltration during peritonitis
challenge.
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2.3.3 Hyperglycemia induces broad macrophage infiltration in organ
tissues
The condition of hyperglycemia also induced increases in macrophage population in
multiple other organs. As shown in Figure 2.3 A, IHC and IF staining of liver sections
revealed marked increases in F4/80+ macrophages lining along endothelial surfaces of
portal vein branches and within sinusoids between hepatocytes in hyperglycemic mice.
Furthermore, this pathological change was further exacerbated when diabetes prolonged
without insulin alleviation. As shown, liver tissues harvested from mice with
hyperglycemia for five months displayed more extensive macrophage infiltration than
those from mice with hyperglycemia for one month. Two groups of mice with blood
glucose levels below and higher than 350 mg/dl showed similar results. In addition, the
liver structure appeared to be deteriorated after prolonged hyperglycemia. Compared to
liver tissues harvested from healthy control mice and the one-month hyperglycemic mice,
the tissue from mice with five-month hyperglycemia exhibited a structurally “loose”
appearance; having displayed deteriorated or shrank hepatocyte lobules, and enlarged
sinusoids that were accumulated with many F4/80+ macrophages (Figure 2.3 A).

Increases in macrophage infiltration were also found in kidneys under hyperglycemia. As
shown in Figure 2.3 B, kidney tissues around the glomeruli, where macrophages are
usually absent, displayed strong staining for F4/80+ macrophages in mice with
hyperglycemia. Increases in F4/80+ macrophages were also observed along the afferent
and efferent vessels and renal tubules. Again, this condition of macrophage infiltration in
kidney was exacerbated when hyperglycemia prolonged from one month to five months.
Further examination for macrophage phenotypes with the M1 and M2 markers, CD86 and
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Dectin-1, respectively, failed to observe definitive staining (Figure 2.3 E). These results
suggest that the increased macrophages in tissues were phenotypically undetermined.

Next, we asked the question of how hyperglycemia caused an increase of macrophage
population in tissues. One possibility is that hyperglycemia induces monocytosis and that
elevated monocyte infiltration into tissues results in an increase of macrophage numbers.
Another possibility is that hyperglycemia stimulates macrophage proliferation in situ. To
address the first possibility, we examined monocytes in the peripheral blood and found
that the population of Gr-1+F4/80+ monocytes, the major tissue-infiltrating monocytes
[99, 100], was significantly expanded in hyperglycemic mice. As shown in Figure 2.4 A,
peripheral Gr-1+F4/80+ monocytes were elevated more than two-fold in hyperglycemic
mice compared to that of the control. In contrast, peripheral Gr-1-F4/80+ monocytes, also
termed resident monocytes, changed only slightly. Insulin treatment of diabetes reversed
the elevation of peripheral Gr-1+F4/80+ monocytes. Since monocytes can be produced by
the spleen and bone marrow [101-103], we further examined monocytes in these organs.
As shown in Figure 2.4 A, the spleen, but not bone marrow, displayed expansion of
monocytes (Ly6Chigh) under hyperglycemia, suggesting that expansion of monocytes in
the circulation were most likely due to increased spleen production. We also tested if
macrophage proliferation in situ served as another mechanism for increasing tissue
macrophages under hyperglycemia. Studies have reported that some tissue macrophages
are formed during embryonic development and are capable of self-replenishing through
proliferation in situ [104-106]. As shown in Figure 2.4 C and D, the majority (> 80%) of
macrophages in the liver and kidneys of hyperglycemic mice displayed positive staining
for the cell proliferation marker Ki-67, suggesting that these macrophages were
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undergoing active proliferation. Comparably, the few macrophages observed in the same
tissues of healthy mice were largely devoid of Ki-67 staining. Examination of F4/80+
peritoneal macrophages from hyperglycemic mice also observed a high rate of
proliferation (> 90% positive of Ki-67 staining). Therefore, broadly increased
macrophages in tissues under hyperglycemia are likely the collective results of augmented
monocyte infiltration and macrophage proliferation in situ. Moreover, we also observed
an expansion of PMN population in the peripheral blood (Gr-1+F4/80-) and bone marrow
(Ly6Ghigh) under hyperglycemia (Figure 2.4 A-B), in agreement with the study reported
by others [107].

2.3.4 Macrophage responses enhanced by hyperglycemia exacerbates
inflammatory conditions
To ask if broadly increased macrophages in tissues would render multi-organ
proinflammatory states, we tested hyperglycemic mice with other inflammatory
challenges. Doxorubicin is a chemotherapy drug that could lead to renal injury
(doxorubicin nephropathy) through glomerulosclerosis and tubulointerstitial nephritis
[93]. Previous studies have shown that doxorubicin nephropathy is tightly associated with
macrophage-mediated inflammation resulting in histological and functional injury [93,
108, 109]. In our experiments, mice with and without hyperglycemia were given
doxorubicin at a nephropathy-effective dose (30 mg/kg) and a sub-effective dose (20
mg/kg) [92]. As shown in Figure 2.5 A, non-diabetic control mice developed proteinuria,
an indicator of kidney injury, only when doxorubicin was given at 30 mg/kg, while remain
asymptomic at 20 mg/kg. However, mice with hyperglycemia displayed hypersensitivity
to doxorubicin, and showed proteinuria even when the doxorubicin dose was 20 mg/kg.
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In addition, at 30 mg/kg, though both control and hyperglycemic mice developed
proteinuria, the latter group was more severe. Subsequent tissue histological studies
confirmed macrophage infiltration associated with doxorubicin-induced injury. As shown
in Figure 2.5 B-C, kidneys from doxorubicin (30 mg/kg)-treated, control mice displayed
scattered, small interstitial inflammatory foci with F4/80+ macrophages, whereas
kidneys from the same-treated hyperglycemic mice displayed large, diffused areas of
inflammation with increased macrophage accumulation. Indeed, predisposition of
F4/80+ macrophages in diabetic kidneys was seen prior to doxorubicin treatment, and
doxorubicin brought about additional macrophage infiltration. As expected, diabetic mice
treated with insulin displayed doxorubicin-induced injury as that which had occurred in
the control, non-diabetic mice (Figure 2.5 A-C).

We also tested another inflammatory condition, DSS-induced colitis, and again observed
that hyperglycemic mice displayed further exacerbated consequences. As shown in Figure
2.6 A-B, upon induction of colitis with 2% DSS, mice with hyperglycemia developed much
more severe cases of colitis, indicated by faster body weight decline and worse clinical
symptoms (e.g. diarrhea) than control, non-diabetic mice. Subsequently, the colitic
hyperglycemic mice succumbed to the condition in 8-9 days, whereas control nondiabetic mice generally lasted to 12-15 days. Dissection of intestines on day 6 during DSS
treatment revealed much more severe intestinal loss in hyperglycemic mice than that in
non-diabetic mice (Figure 2.6 C). Colon sections confirmed that hyperglycemic mice
compared to non-diabetic controls suffered more deteriorated tissue damage (Figure 2.6
D) associated with higher levels of MPO (Figure 2.6 E), suggestive of increased PMN
infiltration into the intestines. Analyses of macrophages in colon tissues (Figure 2.6 F)
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found increased numbers in mucosa and submucosa in hyperglycemic mice even prior to
colitis induction. Macrophages were also found in smooth muscle layers underlying
mucosa where macrophages were normally scarce under healthy conditions. Together,
these results further support our findings suggesting that animals under hyperglycemia
are much more prone to exaggerated inflammatory response, and that broadly increased
macrophages in tissues play a critical role.

2.3.5 Inflammatory response in ob/ob mice
In addition to mice with STZ-induced type 1 diabetes, we have also studied inflammatory
response in ob/ob mice, which had displayed obesity and mild/moderate levels of
hyperglycemia due to insulin resistance [110]. As shown in Figure 2.7 A, the fasting level
of blood glucose in 10-12-week-old ob/ob mice was around 200 mg/dl compared to 164
± 22 mg/dl in healthy wild type mice. We observed slight, or insignificant, increases in
macrophages in peritonea of ob/ob mice compared to WT mice (Figure 2.7 B). Zymosaninduced peritonitis tested in ob/ob mice failed to detect significant, but only slight,
increases of PMN infiltration (Figure 2.7 C) and IL-6 expression (Figure 2.7 D). No
significant increases in F4/80+ macrophages were observed in the liver or kidneys in
ob/ob mice (Figure 2.7 E). Treating ob/ob mice with 2% DSS failed to induce severe colitis
(Figure 2.7 F-G). In fact, ob/ob mice displayed resistance to the colitic condition, as also
reported by others [111, 112]. Therefore, ob/ob mice, though with moderate
hyperglycemia, do not display an enhanced systemic inflammatory state similarly to mice
under STZ-induced type 1 diabetes, suggesting that broadly increased macrophages in
various tissues, but not hyperglycemia per se, play a key role in enhancing PMN
infiltration and tissue injuries during inflammation under diabetes.
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2.4 Disscussion
Chronic disease conditions, although many are restricted in specific local tissues, often
lead to systemic changes in the host immunological system. As demonstrated previously,
we found that animals with ongoing colitis, diabetes, lung inflammation and other chronic
conditions display an alteration of host inflammatory response and significantly
enhanced PMN function, which not only exacerbates the existing condition, and also leads
to overstated reaction when facing a new inflammatory challenge [1-3]. The mechanisms
governing the PMN inflammatory response under different conditions are varied and are
incompletely understood.

In this study, we further investigated the mechanisms that enhance PMN response under
diabetes-associated hyperglycemia versus those under active colitis. As shown by our
results, while PMN response is enhanced under both conditions, the mechanisms
involved are different. Under colitis, IL-17 plays a principle role; IL-17 elevated at the
post-acute/chronic stage of colitis promotes granulopoiesis and primes PMN response
and function [1, 2]. IL-17 also primes tissue macrophages, leading to increased
capabilities of inflammatory cytokine production which in turn promotes PMN
infiltration. Neutralization of IL-17 reverses the enhanced PMN infiltration in colitic mice.
However, the role of IL-17 in STZ-induced diabetes is negligible; neutralization of IL-17
does not reverse the enhanced PMN response, nor does it alleviate the proinflammatory
state. Instead, chronic hyperglycemia leads to increases in macrophages in a wide range
of tissues, resulting in tissue hypersensitivity toward inflammatory challenge. As shown
in the study, substantially increased macrophage numbers in the peritoneum of diabetic
mice led to elevated levels of proinflammatory cytokines, which potently promoted PMN
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recruitment during zymosan-induced peritonitis. Significantly increased numbers of
macrophages were also observed in the liver, kidneys, and intestines. Upon inflammatory
challenges, the increased macrophages in these organs predispose tissues to exaggerated
inflammatory reaction, elevating risks of tissue injury. Testing three inflammatory
conditions including acute peritonitis, doxorubicin-induced nephropathy and DSSinduced colitis obtained consistent result; all supporting the conclusion that excess
macrophages in tissues create a proinflammatory state, which synergizing with PMN
priming, exaggerate inflammatory reactions. Insulin treatment reverses hyperglycemia
and also the proinflammatory state in diabetic mice.

Where and how are the increases in macrophage infiltration of tissues originating under
the diabetic condition? Our studies have revealed at least two mechanisms. One is
through the increase in monocyte production. We show that, instead of bone marrow, the
spleen is the primary site where increased monocytes are produced in diabetic mice. The
spleen serves as an important organ for monocyte production as per reports in recent
years [101-103]. We also show that the increased monocytes under diabetes are
Ly6C+CD11b+; hence they are tissue-infiltrating and contribute to increased tissue
macrophages. The mechanism through which diabetes induces the spleen to boost
monocyte production remains unclear, though increased MCP-1 produced from diabetic
endothelial cells may play a role [35]. MCP-1 also promotes monocyte infiltration into
peripheral tissues to replenish macrophages. The second mechanism responsible for
elevation of tissue macrophages is through macrophage proliferation in situ. In diabetic
mice, significantly increased macrophage proliferation was observed in peritonea, liver,
kidney, and intestines. However, we failed to detect these proliferative macrophages
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skewing toward the M2 phenotype; a polarization that is suggested to associate with
macrophage proliferation [104, 113, 114]. In addition, we also failed to detect
macrophages skewing toward the M1 phenotype in hyperglycemic tissues. Nevertheless,
the substantially increased reservoir of macrophages in tissues augments tissue
sensitivity toward inflammation, rendering vulnerability to inflammation-associated
injury. Moreover, we found that ob/ob mice, though being associated with moderate
levels of hyperglycemia, do not display increased macrophage infiltration in tissues, and
thus do not exhibit a significantly enhanced systemic inflammatory state. As leptindeficient mice, ob/ob mice have been suggested to be associated with defectiveness of
certain macrophage/monocyte functions, due to the critical role of leptin in the activation
of macrophages and monocytes [112, 115, 116]. However, this could also suggest that
insulin resistance per se does not cause the systemic inflammation and that our
observations under STZ-induced type I diabetes/hyperglycemia may not apply to the
insulin resistance condition and/or the early stage of type 2 diabetes prior to b-cell
dysfunction.

In conclusion, the study demonstrates that diabetes is different from chronic colitis and
induces a systemic proinflammatory state primarily through broadly increasing the
macrophage population in various organ tissues. Though additional investigation is
needed to further define the mechanisms, strategies aiming to reduce monocytosis in the
spleen and limit macrophage proliferation in tissues may become important for
controlling diabetic complications in conjunction with hyperglycemia mitigation.
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Figure 2.1 Distinctions of enhanced PMN response in mice with STZ-induced diabetes
and DSS-induced colitis
A) STZ-induced diabetes/hyperglycemia. Mice were s.c. injected with STZ (25mg/kg, 5x
or 50 mg/kg, 5x) or the vehicle (Ctl). Blood glucose levels were measured to confirm the
establishment of hyperglycemia. Once blood glucose level (GLU) reached 200 mg/dl, one
group of STZ mice were treated with insulin twice a day to convert hyperglycemia. B)
Enhanced PMN infiltration in diabetic mice (1 month after STZ injection) during
zymosan-induced peritonitis. PMN infiltration into peritoneum was tested at 0, 2, 4, 6, 8,
16 h post-zymosan injection. C) Enhanced PMN infiltration in both colitis and diabetes.
Healthy control, colitis (12 days of DSS, with or without anti-IL-17 treatments) and STZ
mice with different GLU (1 month after STZ injection, with or without insulin or anti-IL17 treatments) were tested for PMN infiltration at 2 h post zymosan-induced peritonitis.
D) DSS-induced colitis and IL-17 level in serum. 2% DSS in drinking water was
continuously applied, and body weight loss was monitored for the establishment of colitis.
Serum IL-17 levels were evaluated by ELISA. E) Serum cytokine levels in two disease
models. Cytokine levels in serum were evaluated by ELISA. F) PMN ROS production upon
PMA challenge. Bone marrow PMN (1x106) from healthy, colitis and STZ mice were
loaded with 1 mM luminol followed by the stimulation with PMA (1µM), and
chemiluminescence was detected at 37°C in relative light units (RLU) every 30 seconds
over 30 minutes. G) Peak values of PMN ROS curves upon PMA challenge. n=8-10
mice/group. * P<0.05, ** P<0.01, *** P<0.001 versus respective controls. (Since STZ
diabetic mice with different GLU (200-350 mg/dl vs >350 mg/dl) established the similar
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phenotype according to our study, the following results and figures will not further
distinguish these two groups.)
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Figure 2.2 Intensified peritonitis under diabetes is associated with locally increased
proinflammatory macrophages.
A) Increased proinflammatory cytokine level under diabetes (STZ) and colitis during
zymosan-induced peritonitis. IL-6 and CXCL1 levels in peritoneum and serum were
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detected by ELISA at 2 h post-zymosan challenge. B) Increased number of F4/80+
peritoneal macrophages (Mφ) from mice with hyperglycemia compared to healthy mice
or colitic mice without induction of peritonitis. C) In vitro zymosan challenge of
peritoneal macrophages. Peritoneal macrophages obtained by peritoneal lavage were
challenged in vitro with zymosan (0.1mg/ml). IL-6, CXCL1, IL-1β and TNF-α secreted
into the culture media at a series of time points were assayed by ELISA. D-E) Adoptive
transfusion of PMN from healthy (CMTMR labeled, red color) and STZ (or STZ with
insulin treatment; CSFE labeled, green color) mice (1:1 ratio mixed, 3x106 PMN/recipient)
into healthy, STZ or STZ with insulin recipients, followed by testing PMN infiltration
during peritonitis. Figure shows the microscopic analysis of infiltrated PMN from all
types of donors in peritoneal lavage after inducing peritonitis for 2 h, and the total
numbers of all types of donor PMN infiltrated at 2 h post zymosan challenge. n=6-8
mice/group. * P<0.05, ** P<0.01, *** P<0.001 versus respective controls.
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Figure 2.3 Hyperglycemia induces broad macrophage infiltration in multiple organ
tissues.
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A, B) Macrophages were labeled with F4/80 by IHC or IF staining in livers and kidneys
from healthy, STZ (1-month and 5-month of hyperglycemia), and STZ mice with insulin
treatment (1-month). C, D) F4/80+ macrophages in IF staining were quantified as the
corrected total cryosection fluorescence (CTCF) using ImageJ. E) Undetermined
phenotype of F4/80+ macrophages in liver and kidney from STZ 1-month mice. F4/80+
(green) macrophages were co-stained with the M1 and M2 markers (red), CD86 and
Dectin-1, respectively. Control M1 and M2 macrophages were induced from mouse bone
marrow derived monocytes in vitro by overnight treatment with LPS (100ng/ml) + IFNγ
(20ng/ml) and IL-4 (20ng/ml), respectively. F) Fluorescence quantification of liver and
kidney sections from Fig 3E, as CTCF using ImageJ. All results represent at least three
independent experiments with n=6. ** P<0.01, *** P<0.001 versus respective controls.
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Figure 2.4 Monocytosis and local macrophage proliferation in diabetic mice.
A, B) Populations of PMN (black) and monocytes (red) in the peripheral blood, spleen
and bone marrow analyzed by flow cytometry. Cells in the peripheral blood were labeled
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with antibodies against Gr-1 and F4/80. Splenocytes and bone marrow cells were labeled
with antibodies against Ly6C and Ly6G. C, D) Local macrophage proliferation in livers
and kidneys from STZ mice. Tissues were co-stained with antibodies against F4/80 (red)
as a macrophage marker and Ki-67 (green) as a cell proliferating marker. IF staining were
quantified as CTCF using ImageJ. All results represent at least three independent
experiments with n=6. ** P<0.01, *** P<0.001 versus respective controls.
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Figure 2.5 Augmented macrophage inflammatory response under hyperglycemia
intensifies doxorubicin nephropathy.
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A) Doxorubicin-induced nephropathy/proteinuria. Healthy and STZ (1 month, with or
without insulin treatment) mice were i.v. injected with one dose of doxorubicin (20 mg/kg
or 30 mg/kg). Urine samples were collected daily and urine albumin/proteinuria was
tested by ELISA. n = 6 mice/group. B) F4/80 IF staining of same kidney samples from
Figure 2.5 C were quantified as the corrected total cryosection fluorescence (CTCF) using
ImageJ. C) Macrophages infiltrated in to kidneys were labeled with F4/80 by IHC
staining. Kidney samples were obtained from control, STZ or STZ with insulin mice at day
7 of doxorubicin (30 mg/kg, one dose) administration. Results represent at least three
independent experiments with n=6. ** P<0.01, *** P<0.001 versus respective controls.
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Figure 2.6 Exaggerated DSS-induced colitis in hyperglycemic mice.
A) Body weight loss and survival curve of diabetic mice during DSS-colitis. 2% DSS in
drinking water was continuously applied to control, STZ or STZ with insulin treatment
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mice. B) Disease activity index (DAI) was evaluated on day 6 of DSS administration. C, D)
Colon lengths and H&E staining of colon tissues at day 6. E) MPO assays of colon
specimen with the same length (2 mm each, 3 specimens from 1 colon) that were
randomly dissected from the entire colon followed by the homogenization. F) Enhanced
infiltration of macrophages in the colon tissue of STZ mice. Macrophages were labeled
with F4/80 by IF staining and quantified as CTCF using ImageJ. n=6 mice/group.
*P<0.05, ** P<0.01, ***P<0.001 versus respective controls.
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Figure 2.7 Comparison of systemic inflammation in C57BL/6 WT mice, type 1 diabetic
WT mice induced by low dose STZ (1-month) and ob/ob mice (10-12 weeks old).
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A) Fasting blood glucose levels. B) Peritoneal macrophage numbers. Note that no
significant difference between WT healthy and ob/ob mice. C, D) Mildly increased PMN
and elevated serum IL-6 in ob/ob mice at 2h of zymosan-induced peritonitis. E)
Macrophages in livers and kidneys from WT healthy mice, WT diabetic mice and ob/ob
mice, labeled by F4/80 via immunofluorescence staining. Fluorescent images were
quantified using ImageJ. F, G) ob/ob mice exhibited only mild colitis with 2% DSS
treatment. n=6 mice/group. *P<0.05, ** P<0.01, ***P<0.001 versus respective controls.
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IDENTIFICATION OF LPS-PRIMED CD11B+ LEUKOCYTES AS THE
EFFECTIVE CARRIER OF SHIGA TOXIN 2 CAUSING HEMOLYTIC
UREMIC SYNDROME IN MICE

3.1 Introduction
Shiga toxin (Stx)-producing E. coli (STEC) are vicious food-borne pathogens that cause
over 2 million acute illnesses annually worldwide, among which several thousand require
hospitalization and hundreds succumb to death [41, 46, 117, 118]. Severe bacteria-induced
enteritis with heavy diarrhea, both watery and bloody, is the major manifestation of STEC
infection; however, the fatality sometimes occurs when the subsequent, life threatening
complication hemolytic uremic syndrome (HUS) develops [5, 7, 38, 39]. The HUS
condition, characterized by hemolytic anemia, acute kidney failure (uremia) and
thrombocytopenia, often happened abruptly at the post-acute, or even the recovery stage
of STEC-induced enteritis. Different from STEC infection that is restricted in intestines,
HUS development is associated with the spread of Stx to target organs such as kidneys,
where high affinity cell surface receptors such as globotriaosylceramide (Gb3) mediate
Stx internalization, resulting in cellular toxicity [9, 48, 119, 120]. Two types of toxins, Stx1
and Stx2, can be produced by STEC, with Stx2 possessing much higher potency of toxicity.
No specific therapeutics are available for treatment of HUS, and that traditional
antibiotics against bacteria show promotion of toxin expression from the lysogenized
phage that typically carries the Shiga toxin (Stx) gene, thus tend to exacerbate the disease
condition [43]. Another challenge for clinicians is the inability to predict which STECinfected patients would develop severe HUS and which would simply recover from the
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early enteritis as indicators for clinical tests predicting HUS occurrence are still lacking
[42].

One major dilemma in HUS is the mystery of how Stx travels from STEC-infected
intestines to kidneys. The possibility of passive dissemination, though not been
completely excluded, has been considered low as no free Stx have been detected in the
serum of HUS patients [121, 122]. Instead, circulating leukocytes have been suggested to
serve as the carrier that delivers Stx to distant organs [10, 11]. In humans, some studies
implicate neutrophils are the carrier. These studies reported observations of Stx direct
binding to human neutrophils [10, 50] and the interference of the binding by LPS,
suggesting that Toll-like receptor 4 (TLR4) is likely the receptor [51, 52]. However, other
studies either failed to replicate Stx binding to human neutrophils or demonstrated that
the binding was unspecific or weak, raising uncertainty of whether neutrophils to be the
true carrier [53, 54]. Stx binding to leukocytes has also been shown in an in vitro study
co-incubating Stx with isolated, total porcine peripheral leukocytes; however, this study
did not reveal which population of leukocytes bound to the toxin and whether these
leukocytes deliver toxin in vivo leading to HUS [55]. In mice, a study demonstrated that
Stx2 is capable of binding to murine neutrophils, but the binding is through Gb3, leading
to toxin internalization [56]. This study not only contradicts to the finding in humans in
which Stx binding to neutrophils is independent of Gb3 [9, 52], but also raises the
question of whether neutrophils would deliver the toxin in the body without degrading it
intracellularly. In addition to these dilemmas, a recent study reported the finding of Stx
in serum microvesicles [123], further baffling the exact carrier for Stx elusive. One
particular drawback, as it worthy to mention, is that most experiments previously for
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identifying the toxin carrier were in vitro cell binding assays, relevant minimally to the
actual disease development; approaches are thus needed to directly determine the Stx
carry in vivo that leads to HUS.

In this study, we employ the LPS-Stx2 murine HUS model [74, 124] and further examine
peripheral blood for the role in Stx carry and delivery and HUS-causing in vivo. Our data
show that circulating myeloid leukocytes of CD11b+ in LPS-primed mice are highly
effective in carrying of Stx2 in vivo. Brief exposure of these leukocytes to Stx2, even ex
vivo, results in toxin binding and enables their capability to cause HUS in vivo. In
addition, we demonstrate for the first time that LPS-induced systemic inflammation
significantly alters myeloid leukocytes to become highly capable Stx2 carriers, which in
conjunction with enhanced leukocyte infiltration in toxin-afflicted tissues, aggravate
kidney damage and accelerate the HUS condition.

3.2 Materials & Methods
3.2.1 Murine LPS-Stx2 HUS model
LPS priming Stx2-induced HUS (LPS-Stx2 HUS) in mice [74] was established for the
study. C57BL/6 mice (6-10 weeks old, 18-22 g) purchased from the Jackson Laboratory
were housed in a pathogen-free animal facility. Stx2 purified from STEC was obtained
from the Phoenix Laboratory at Tufts Medical Center (Boston, MA). To induce HUS in
mice, one dose LPS (300 g/kg, Sigma-Aldrich) was first administered intraperitoneally
(i.p.) to prime the mice. After 24 h, Stx2 was given via i.p. at the dose of 500 ng/kg. The
injections of Stx2 were performed on the same mice for three times at every 24 h interval.
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The appropriate dose of Stx2 to induce HUS was determined in initial pilot studies, in
which various doses ranging from 100 ng/kg to 100 g/kg were tested (data not shown).
Body weight loss was monitored after LPS and Stx2 administrations; peripheral blood
samples were collected at due point for analyses.

3.2.2 Peripheral blood work
Peripheral blood was collected by cardiac puncture with anti-coagulation (0.1 ml of 3.8%
sodium citrate per ml of blood). After centrifugation (150 x g, 10 mins, 4 °C), blood was
separated into platelet-rich plasma (PRP), white blood cells (WBC) and red blood cells
(RBC). PRP was collected followed by further centrifugation (5000 x g, 10 mins, 4 °C) to
obtain platelets (PLT) and platelet-free plasma (PFP). WBC were isolated from the buffy
coat followed by lysis of RBC using RBC lysis buffer (0.15 M NH4Cl, 10 mM NaHCO3, 0.1
mM EDTA). In some experiments, WBC were further separated into CD11b+ and CD11bleukocyte sub-populations using a PE-conjugated anti-mouse CD11b antibody
(BioLegend) and EasySep™ release mouse PE positive selection kit (STEMCELL
Technologies). To determine peripheral reticulocytes, 3 drops of isolated RBC were mixed
with 1 drop of Reticulocyte Stain (Sigma-Aldrich; 10 mins, room temperature) followed
by smearing on a microscope slide and counting of reticulocytes per 1000 RBC. Increasing
of reticulocytes in blood is an indicator of hemolytic anemia under HUS. Blood urea
nitrogen (BUN) levels were determined by spectrophotometer using a BUN reagent set
(Pointe Scientific). Plasma creatinine levels were determined using Creatinine
Colorimetric Assay Kit (Cayman Chemical). Elevated BUN and creatinine indicate renal
dysfunction during HUS development.
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3.2.3 Adoptive transfer
To transfer blood components from LPS-Stx2 induced HUS mice to non-HUS recipients,
peripheral blood samples were collected from donor HUS mice 4 h after the 2nd Stx2
administration, followed by separation into WBC, RBC, PLT and PFP. Adoptive transfer
was then performed by transfusion intravenously (i.v.) of donor PFP (0.3 ml) or cell
samples including WBC (1 x 106), RBC (1 x 108) and PLT (5 x 108) in 0.3 ml PBS via a tail
vein into recipient mice that had been primed with one dose LPS (300 g/kg) 24 h earlier.
Blood component transfer from HUS mice to recipients was repeated every 24 h for twothree rounds. Control experiments were performed by transferring blood components
from healthy donor mice or the carrier solution PBS to LPS-primed mice. Prior to and
after the adoptive transfer, the recipient mice were monitored for body weight change.
The recipient mice were euthanized after the 3rd adoptive transfer and blood urea
nitrogen (BUN) and creatinine, as well as peripheral reticulocytes and thrombocytopenia,
were determined.

3.2.4 Ex vivo Stx2 treatment
Peripheral WBC, RBC or cells from each fraction of bone marrow (1 x 106 cells
each), or PLT (5 x 108) from LPS-primed mice or healthy mice were incubated with Stx2
(10 ng/ml) ex vivo in PBS (0.5 ml, 30 min, 25°C). The cells were then washed thoroughly
with PBS (5 x) to remove excess Stx2 followed by suspension in PBS (150 µl) and adoptive
transfer into LPS-primed recipients (1 x 106 total WBC, 1 x 106 CD11b+ or CD11bleukocytes, 1 x 108 RBC, 5 x 108 PLT, or 1 x 106 bone marrow cells per mouse). Control
experiments were done by adoptive transfer of mice with cells that had not incubated with
Stx2 or with the carrier solution PBS.
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3.2.5 Bone marrow (BM) cell isolation and fractionation
Mouse BM were harvested from femur and tibia bones. After lysis of RBC, whole BM cells
were fractionated using discontinuous Percoll™ (GE Healthcare) density gradients
consisting of layers of 75%, 60%, 50%, and 40% of Percoll density solutions (2 ml per
layer) prepared following the sequential decreasing order from the bottom to the top in
15 ml centrifugation tubes. Prepared BM cells in 2 ml PBS were laid on top of the gradients
followed by centrifugation at 1800 x g for 40 min (18°C). Four cell-rich bands were formed
at the density interfaces of 0-40%, 40-50%, 50-60% and 60-75% (fractions I, II, III and
IV, respectively) after the centrifugation and cells in each band were collected. After wash
with PBS to remove excess Percoll, cells in different fractions were determined by flow
cytometry for granulocytes (Ly6G+), monocytes (Ly6Chigh), myeloid leukocytes
(CD11b+Gr-1+), B lymphocytes (B220+), etc. Antibodies with fluorophore conjugations
for flow cytometry were obtained from (BioLegend).

3.2.6 Stx2-FITC and toxin-cell binding determination
Fluorescein isothiocyanate (FITC) (Pierce) was chemically conjugated to Stx2 using the
EZ-Label FITC Protein Labeling Kit (Thermo Scientific). Briefly, Stx2 (0.1 mg) was
incubated with FITC (10 µg) in borate buffer (0.1 ml, pH 8.5) for 2 h (25°C). The labeling
reaction was then quenched with 100 mM Tris buffer (pH 7.5), followed by extensive
dialysis against PBS to remove the excess uncoupled FITC. For cell surface labeling, WBC
(1 x 106) isolated from LPS-primed mice and non-primed mice were incubated with Stx2FITC (10 ng/ml) in 0.5 ml PBS for 30 min. A special note is that the concentration of Stx2FITC used in the labeling should reference the in vivo effective dosage of Stx2, which is
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very low; over-use of Stx2-FITC produces high degree non-specific binding. After
labeling, the cells were washed, followed by labeling with Pacific Blue™-conjugated antimouse CD11b (BioLegend) and flow cytometry.

3.2.7 Statistical analyses
Data represent at least three independent experiments and are expressed as the mean ±
SEM. The reported p value was 2-tailed. Differences were considered statistically
significant at P < 0.05, as analyzed using the Student t-test for paired samples and oneway ANOVA for k > 2 samples.

3.3 Results
3.3.1 Establishment of Murine HUS model using LPS-Stx2
To induce HUS, C57BL/6 mice were first given one dose of LPS (300 µg/kg, i.p.). After 24
h, the same mice were intraperitoneally administrated with Stx2 (500 ng/kg), followed
by two additional Stx2 administrations, each given in a 24 h interval (the scheme is shown
in Figure 3.1 A). As shown in Figure 3.1 B-H, LPS priming followed by Stx2
administrations (LPS-Stx2) rapidly induced HUS development, demonstrated by body
weight loss, thrombocytopenia, anemia (increased peripheral reticulocytes), and
significantly elevated creatinine and BUN levels in the circulation indicative of renal
dysfunction. Kidney failure was evident after 2 days following the LPS-Stx2 treatments
when urinary output became deficit. All mice treated with LPS-Stx2 succumbed to HUS
in 3-4 days. Comparably, mice primed with LPS alone experienced transient, slight weight
loss, without signs of thrombocytopenia, anemia or renal dysfunction. Mice given Stx2
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without LPS priming developed similar, but delayed appearance or mild HUS symptoms;
these mice would also progress to HUS lethality but require higher doses of toxin (1-3
µg/kg), more frequent treatments (> 4 treats), and/or a longer time period. These results
were in agreement with previous studies by others using Stx2-induced HUS mouse
models with LPS priming [74, 125].

3.3.2 WBC in the peripheral blood served as the potential carriers of Stx2
As Stx2 was given intraperitoneally, it needed to travel to kidneys in order to cause kidney
damage. To determine if circulating blood played a role in carrying Stx2 to kidneys,
peripheral blood samples were collected from mice with LPS-Stx2 induced HUS, in which
when the HUS condition was developing (4 h after the 2nd Stx2 administration). These
HUS blood samples were separated into platelet-free plasma (PFP), platelets (PLT), RBC
and WBC by differential centrifugations, followed by adoptive transfer (i. v.) of each
component into recipient mice that were similarly primed by LPS but without Stx2
administration (Figure 3.2 A). A total of three rounds of blood component transfer was
performed in every 24 h interval. As shown in Figure 3.2 B-C, recipient mice, though never
been directly exposed to Stx2, developed HUS after receiving WBC from LPS-Stx2 donors;
the mice transferred with WBC demonstrated characteristic HUS symptoms including
body weight loss, thrombocytopenia and renal dysfunction. Indeed, these WBC causing
HUS in recipient mice were in the way similar to that when LPS-Stx2 was used to induce
HUS. In contrast, recipient mice in which PFP, PLT, or RBC were transferred from the
same LPS-Stx2 donors failed to develop HUS. In conclusion, these results showed that
WBC from HUS-inflicted mice were capable of transferring the disease to non-HUS
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animals, suggesting that WBC serve as the Stx2 carrier, bearing Stx2 to distant target
organs. Other blood components such as PFP, PLT and RBC were not the toxin carrier.

To further confirm that WBC can carry Stx2, hence contribute to HUS development and
kidney failure, we isolated WBC from non-HUS mice and tested if ex vivo exposure of
WBC to Stx2 would enable the capability of causing HUS. In these experiments, WBC, as
well as other types of cells, isolated from peripheral blood of LPS-primed mice were
incubated with Stx2 (20 ng/ml) ex vivo for 30 min (25°C) followed by thorough washing,
prior to transfer into recipient mice. Since bone marrow (BM) contained reservoirs of
WBC, these cells were also isolated, similarly treated with Stx2 ex vivo, and transferred
into recipients. As shown in Figure 3.3, ex vivo Stx2-treated WBC and BM cells rapidly
induced HUS in recipient mice, inferring that WBC bound to Stx2 during the ex vivo
exposure, carried toxin in vivo and caused disease. Conversely, ex vivo exposure to Stx2
did not enable RBC or platelets to cause HUS.

3.3.3 Identification of CD11b+ leukocytes as the carriers of Stx2
Since WBC are heterogeneous, comprising CD11b+ myeloid leukocytes and CD11blymphocytes (Figure 3.4 A), we performed further separation by antibody-mediated
positive selections using immunomagnetic beads. Subsequent exposure of CD11b+ and
CD11b- cells to Stx2 ex vivo and then testing the capability of causing HUS in vivo
demonstrated that only CD11b+ myeloid leukocytes carried Stx2 leading to HUS. As
shown in Figure 3.4, between the two populations of peripheral WBC, both being treated
with Stx2 ex vivo, CD11b+ leukocytes but not CD11b- lymphocytes effectively induced HUS
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in recipient mice. We also further separated BM cells by Percoll density gradients, which
enriched CD11b+ myeloid leukocytes to high density fractions between the Percoll
densities of 50-60% and 60-70% (fractions III and IV) (Figure 3.5 A). In agreement with
our other studies, the CD11b+ fraction III contained Ly6Chigh monocytes and immature
Ly6G+ granulocytes (approximately 40% and 60%, respectively), while the highest
density, CD11b+ fraction IV were nearly completely mature Ly6G+ granulocytes (> 95%)
(Figure 3.5 B). There were low density fractions (I and II), which contained chiefly CD11blymphocytes, progenitors and stroma cells. After cell separation and washing, different
fractions of BM leukocytes were exposed to Stx2 ex vivo by co-incubation, prior to transfer
into recipient mice. As shown in Figure 3.5 C, the fraction IV granulocytes displayed a
strong capability to carry Stx2 and cause HUS in recipients, while the fraction III
displayed partial effects and induced relatively mild, delayed HUS symptoms. Conversely,
BM cells from the low density fractions (I and II) failed to induce HUS in vivo. In
conclusion, these results together support that CD11b+ leukocytes in the WBC population
serve as the Stx2 carrier during HUS development.

3.3.4 Pre-administration of LPS modulated the binding and delivery of
Stx2 by CD11b+ leukocytes in vivo
Interestingly, we found that CD11b+ leukocytes isolated from LPS-primed mice and mice
without priming displayed different potencies in inducing HUS, even the same ex vivo
Stx2 exposure ensued. As shown in Figure 3.6 A-C, after co-incubation with Stx2, CD11b+
leukocytes from LPS-primed mice exhibited much stronger capability of inducing HUS
than those from healthy mice (non-LPS priming); after the adoptive transfer, recipient
mice with the former leukocytes demonstrated faster body weight loss and more profound
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renal dysfunction than mice with the latter. Since the number of CD11b+ leukocytes used
for adoptive transfer was the same for either donor mice, the varied effectiveness in
inducing HUS suggests that LPS priming significantly augmented CD11b+ leukocytes
binding to and/or carrying of Stx2, whereas leukocytes without priming had only weak
toxin delivery capacity. Binding of CD11b+ leukocytes with FITC-labeled Stx2 confirmed
this fact, showing increased frequencies of toxin binding to leukocytes from LPS-primed
mice than those from non-primed mice (Figure 3.6 D). LPS priming of mice might also
enhance leukocyte infiltration into Stx2-inflicted organs, further aggravating tissue
damage. Together, our results suggest that LPS-induced systemic inflammation plays a
significant role in promoting HUS; it “primes” CD11b+ leukocytes for more binding to
Stx2, rendering these leukocytes to become effective toxin disseminator that leads to
HUS.

3.4 Discussion
Due to the broad sources of STEC transmission such as consumption of contaminated
food and water, or direct contact with infected persons or animals, outbreaks of STEC
occur frequently each year causing millions of illnesses. While STEC infection is restricted
to the intestines, patients, especially children and elders, are at risk for developing the
Stx-caused, severe extra-intestinal complication HUS. Approximately 10% of STECinfected patients develop HUS in clinics, and acute kidney failure is among the most
common reasons leading to lethality. STEC produce two types of bipartite toxins, Stx1 and
Stx2, both of which contain an A subunit and five B subunits (AB5). The B subunits
mediate cell attachment through binding to cell surface receptors, while the A subunit
possesses enzymatic activity that cleaves the adenine nucleotide in ribosomal RNAs and
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DNA, resulting in ribosome and gene damage [7, 8, 126, 127]. A few cell types including
renal epithelial cells express the high affinity receptors for the B subunits, rendering
kidneys to be the vulnerable toxin targets [48, 128, 129]. However, STEC are non-invasive
bacteria restricted in intestines; for causing cell damage in kidneys, STEC-produced Stx
must be transported from intestines to the kidney. No specific diagnostic methods
predicting HUS, in part, for the fact that mechanisms lead to Stx spread from bacteriainfected intestines to kidneys remain unclear. The establishment of murine models of Stxinduced HUS is an important step in research, allowing for further mechanistic
investigations and identification of the Stx delivery pathway in vivo. Interestingly, the
initial studies of these models indicated that, in addition to Stx administration, LPS
administration is preferable to induce a lethal condition of HUS that mimics pathological
processes in human disease [74, 125]. Merely administration of Stx2 induces less severe
and partial symptoms of HUS, or requires higher doses and/or a longer period for the
disease development [74].

Utilizing the LPS-primed mice to induce HUS by Stx2 (LPS-Stx2 HUS model [74, 124,
125]) in mice, we asked whether, or which circulating blood cells have the ability to carry
toxin to kidneys leading to HUS in vivo. Four sequential experiments were performed in
this study and together led to the conclusion that CD11b+ myeloid leukocytes act as the
exclusive toxin carrier, which directly binds to Stx2 and carries the toxin to kidneys
causing lethal HUS in vivo. First, we harvested peripheral blood cells and the cell-free
plasma from LPS-Stx2 treated mice in which severe HUS was developing, and transferred
these components to recipient mice that had no prior Stx exposure. These experiments
showed that peripheral WBC, but not other cells, from mice with HUS carried toxin and
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transferred the disease to recipients. These experiments also concluded that Stx spreads
through cell carriers as the cell-free plasma from the same HUS mice failed to transfer
disease, suggesting this component being devoid of toxin. Also for the same reason, it is
concluded that circulation of extracellular microvesicles [123] is not the main channel for
the toxin dissemination. Second, we tested circulating blood cells from non-HUS mice
briefly exposed to Stx2 ex vivo for the ability of causing HUS in vivo after adoptive
transfer into recipients. The results showed that WBC, as well as WBC-rich BM cells, after
ex vivo exposure to Stx2 gained capability of inducing HUS, suggesting that these cells
directly bound to Stx2 ex vivo and carried the toxin in vivo. In the third experiments, we
further separated peripheral WBC into CD11b+ myeloid leukocytes and CD11b- others, and
defined that the former leukocytes serve as the Stx2 carrier. Brief exposure to Stx2 ex vivo
is sufficient for CD11b+ myeloid leukocytes to cause HUS in vivo. In all the “trans”induced HUS experiments performed by adoptive transfer of Stx2-exposed leukocytes,
renal dysfunction was evident, suggesting the Stx2-bore leukocytes carrying toxin to
kidneys via circulation. Lastly, we tested leukocytes from mice with and without LPS
priming for capturing of Stx2 ex vivo followed by causing HUS in vivo. These experiments
demonstrate that LPS priming significantly increases CD11b+ leukocytes for binding to
toxin.

LPS promoting Stx2-induced HUS in mice has been shown in the initial disease
modeling [74, 124, 125] , but the mechanisms accountable for this effect were unclear.
From this study, we predict that the mechanisms are two-fold, both attributing to LPSinduced systemic inflammatory response. One is that the elicited inflammatory response
promotes leukocyte infiltration and leukocyte-mediated damaging function. In Stx-
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induced HUS, enhanced leukocyte infiltration and damaging in kidneys certainly
aggravates injury deposited by Stx toxicity, hence accelerating kidney failure. Another
critical mechanism for LPS promoting Stx-induced HUS, as revealed by this study, is that
LPS treatment alters CD11b+ leukocytes, resulting in the production of highly effective
Stx2 carriers. It is unclear how LPS achieves this, whether through directly signaling on
leukocytes, or by inducing inflammatory cytokines, which then “re-program” leukocytes,
leading to changes of the cell surface molecular expression and the presentation of Stx2
receptor(s). From our data, it appears that both the leukocyte receptor number and the
binding capability are increased in LPS-primed mice compared to those in non-primed
littermates (Figure 3.6 D). These views of LPS aggravating Stx2-induced HUS in mouse
models match with clinical cases of STEC-associated HUS in humans, in which STEC
infection imparts enteritis along with the Stx toxin. Perhaps, the systemic inflammation
subsequent of the initial enteritis leads to innate leukocyte changes, rendering some
CD11b+ leukocytes to become potent Stx carriers. Indeed, this conception is in agreement
with other studies of intestinal inflammation [1, 118, 130], in which innate leukocytes were
observed changing protein expressions, and also would provide an explanation of why
severe HUS in clinics often occurs at the post-acute or even resolution stage, a delayed
phase until leukocytes becoming effective toxin carrier. Clearly, these postulations of LPS
promotes Stx-induced HUS requires further investigations, and important findings of
Stx2 receptors on leukocytes and how dysregulated inflammation promotes HUS will
bring medical innovations, both diagnosis and therapeutics, for treating STEC-associated
HUS.
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Figure 3.1 LPS-Stx2 induced HUS in mice.
A) The induction schemes. Mice were primed with LPS (300 µg/kg, i. p.) a day prior to
three consecutive Stx administrations (500 ng/kg, i. p. every 24 h). Controls were mice
administrated with LPS alone or PBS (saline). B-F) Determination of HUS. Starting from
the LPS treatment, mouse body weight (B) was recorded daily. C) Mouse survival rate
through the HUS induction. The clinical diagnostic triad including hemolytic anemia,
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thrombocytopenia and renal dysfunction detected by assaying increases in peripheral
reticulocytes (D), reduction of peripheral platelets (E), and increases in the plasma
creatinine and urea nitrogen (BUN) levels (F). Data represent over three independent
experiments; n= 10, * p < 0.05, ** p < 0.01, *** p < 0.001 versus controls.
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Figure 3.2 HUS transmission by peripheral white blood cells (WBC) of Stx2-induced HUS
mice.
Peripheral blood was obtained from LPS-Stx2 -treated mice (donors) during HUS
development. The blood components including WBC, RBC, platelets (PLT) and PLT-free
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plasma (PFP) were separated and transferred intravenously (i. v., every 24 h) into mice
(recipients) that were administrated with LPS (300 µg/kg, i. p.) a day earlier (priming).
A) The experimental scheme; B-D) HUS development in recipient mice. Data show the
body weight loss (B), and the appearance of thrombocytopenia (C) and renal dysfunction
indicated by evaluated plasma creatinine and urea nitrogen (BUN) levels (D) 72 h after
the adoptive transfer. Data represent four independent experiments; n = 6; * p < 0.05, **
p < 0.01, *** p < 0.001 versus controls in which recipient mice were administrated (i. v.)
with saline.
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Figure 3.3 Ex vivo exposure to Stx2 confers WBC capability causing HUS.
Peripheral blood WBC, RBC and PLT, as well as bone marrow (BM) cells, were isolated
from LPS-primed, non-HUS mice. The cells were then incubated ex vivo with Stx2 (10
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ng/ml in PBS) for 30 min (25°C), followed by thorough wash and transfer (i. v.) into other
LPS-primed mice (recipients). A) The experimental scheme; B) HUS development in
recipient mice assessed by body weight loss (B), thrombocytopenia (C) and renal
dysfunction (D). Data represent four individual experiments; n = 6; * p < 0.05, ** p <
0.01, *** p < 0.001 versus controls in which recipient mice were administrated (i. v.) with
saline.
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Figure 3.4 CD11b+ myeloid leukocytes carry Stx2 and cause HUS in vivo.
Peripheral WBC from LPS-primed, non-HUS mice were further separated into CD11b+
and CD11b- leukocyte populations by antibody-facilitated positive selection. After brief
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incubation (30 min) with Stx2 (10 ng/ml in PBS) ex vivo and wash, two populations of
leukocytes were transferred (i. v.) into different, LPS-primed recipient mice (A). HUS
development in recipient mice assessed by body weight loss (B), thrombocytopenia (C)
and renal dysfunction (D). Data represent two individual experiments; n = 6; * p < 0.05,
** p < 0.01, *** p < 0.001 versus controls in which recipient mice were administrated
(i. v.) with saline.

81

82

Figure 3.5 Myeloid leukocytes from BM also have the capability of carrying Stx2.
Total BM cells from LPS-primed, non-HUS mice were fractionated by Percoll density
gradients into non-myeloid cells (Fr. I and II) and myeloid leukocytes (Fr. III and Fr. IV)
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following a protocol described previously. The separated populations were incubated with
incubated with Stx2 (10 ng/ml in PBS) ex vivo, followed by thorough wash and transfer
into other LPS-primed mice (recipients) (A).

HUS development in recipient mice

assessed by body weight loss (B), thrombocytopenia (C) and renal dysfunction (D). Data
represent two individual experiments; n = 6; * p < 0.05, ** p < 0.01, *** p < 0.001 versus
controls in which recipient mice were administrated (i. v.) with saline.
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Figure 3.6 LPS priming promotes CD11b+ leukocytes binding to Stx2.
CD11b+ leukocytes isolated from LPS-primed and non-primed donors were incubated
with Stx2 (10 ng/ml in PBS) ex vivo, followed by washing and transfer into recipient mice
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with LPS priming. A) Experimental scheme. B) Increased frequencies of Stx2-FITC
binding to CD11b+ leukocytes from LPS-primed mice than those from non-primed mice
analyzed by flow cytometry. C-E) HUS development in recipient mice assessed by body
weight loss (C), thrombocytopenia (D) and renal dysfunction (E). Data represent two
individual experiments; n = 6; * p < 0.05, ** p < 0.01, *** p < 0.001 versus controls in
which recipient mice were administrated (i. v.) with saline.
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4

CONCLUSIONS

Sub-acute/chronic inflammation dynamically regulates innate immune cell response. In
the first study using DSS-induced colitic mice and STZ-induced diabetic mice as subacute/chronic inflammatory models, we demonstrate that different from colitis, diabetes
presents a systemic proinflammatory state primarily through broadly increasing the
macrophage population in various organ tissues. Once facing a secondary inflammatory
challenge,

increased

macrophages

not

only

directly

provide

enhanced

local

proinflammatory responses, but also recruit increased number of PMN to the
inflammatory site, which both result in exacerbated tissue damage. Reversing
hyperglycemia using insulin significantly relieves such exacerbation, which emphasizes
the clinical importance of maintaining a stable and normal blood glucose level in diabetic
patients. Though additional investigation is needed to further define the mechanisms of
how macrophages are modified under hyperglycemic condition, strategies aiming to
reduce monocytosis in the spleen and limit macrophage proliferation in tissues may
become important for controlling diabetic complications in conjunction with
hyperglycemia mitigation.

In the study of identifying the carrier of Stx2 that causes HUS, we demonstrate that
CD11b+ leukocytes in the peripheral blood bind to and deliver Stx2 to the target end
organs in vivo. More importantly, we discover that pre-existing inflammation induced by
low dose LPS escalates the capability of CD11b+ leukocytes delivering Stx2 and inducing
HUS. This may provide an explanation of the “window period” observed in HUS patients,
where the potential carriers of Stx may undergo “re-programming” due to the pre-existing
inflammation (enteritis), to become a higher affinity toxin carrier, resulting in a sudden
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and robust HUS. Clearly, the mechanism of such “re-programming” on toxin carrying
ability of CD11b+ leukocytes require further investigations. Nevertheless, important
findings addressing the mechanisms of how CD11b+ leukocytes (or its sub-type) become
better Stx carriers will contribute to early detection and therapeutic innovations in
treating STEC infection-associated HUS.

Several studies by others suggest that PMN in human is capable of binding Stx [10, 11, 50,
129], possibly through TLR4 as the binding site [52]; however, very few in vivo evidence
supports the role of PMN as the sole carrier of Stx that is responsible for directly causing
HUS. Those studies also failed to address why adults other than children and seniors have
a very low incidence of HUS, given that PMN composes more than 50% of the WBC
population circulating in a normal adult. Interestingly, our further studies using murine
HUS model suggest that a subtype of CD11b+ WBC, rather than PMN, which are CCR3+
eosinophils, exhibits the highest capability of binding to Stx2 upon LPS-priming (data not
shown). Although it requires more intensive investigation on whether this group of cells
carries and delivers Stx2 to target organs causing HUS, our observation may provide an
important alternative route to better understand the pathogenesis of such a devastating
disease HUS, and the relationship between Stx, the carrier cells, and the target distal
organs such as the kidneys.
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